Megace

(Megestrol)

Phase 2Small molecule

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Megace is one of 35 small molecule programs targeting Anorexia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Nausea and VomitingActive, not recruiting

Nausea and VomitingPhase 2

Active, not recruiting

Competition

Competitive Landscape

224 competitors in Nausea and Vomiting

#DrugCompanyPhaseTrials

Aloxi

AAvyxa

Preclinical

27 2

Megace

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

1 3

Alfenta

Alnylam Pharmaceuticals

Preclinical

1 4

Ramosetron

Astellas

Preclinical

15 5

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

7 6

Phenergan

BBassett Healthcare

Preclinical

5 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 8

Haldol

DDePuy Orthopaedics

Preclinical

3 9

Cytoxan

BBaxter Healthcare Corporation

Preclinical

2 10

Adriamycin

GGynecologic Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Children1 trial

Trial of Amitriptyline for Chronic Oral Food Refusal in Children 9 Months to 8 Years of Age

Completed·—·Phase 2·NCT01206478·21 enrolled

Chemotherapy1 trial

Metronomic Chemotherapy by Cyclophosphamide Versus Megestrol in Palliative Cancer

Completed·CCentre Oscar Lambret·Phase 2·NCT00420563·88 enrolled

Anorexia1 trial

Comparison Between Mirtazapine and Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care.

Completed·UUniversity of Sao Paulo·Phase 2·NCT03283488·52 enrolled

Megestrol Acetate1 trial

Randomized Placebo-Controlled Study of Aerobic Exercise and Resistance Training Plus Megestrol Acetate for HIV-Wasting

Completed·NNational Center for Research Resources (NCRR)·N/A·NCT00004664·69 enrolled

Nausea and vomiting1 trial

the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy

Unknown status·HHenan Cancer Hospital·Phase 2·NCT04430361·120 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

MEGACE

NDA NDA016979

Sep 10, 1993

MEGACE

NDA NDA020264

Jul 5, 2005

MEGACE ES

NDA NDA021778

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Megestrol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Megestrol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Megestrol. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA021778). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Karuna Therapeutics, Inc., a Bristol Myers Squibb company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Megace

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Children1 trial

Chemotherapy1 trial

Anorexia1 trial

Megestrol Acetate1 trial

Nausea and vomiting1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News